SANOFI-AVENTIS U.S. LLC - NEW AWARD FOR HUMAN INSULIN WITH SANOFI-AVENTIS US LLC. ORDERING PERIOD IS JULY 1, 2025 TO JUNE 30, 2026 WITH FOUR ONE-YEAR OPTIONS"
Key Details
Description
NEW AWARD FOR HUMAN INSULIN WITH SANOFI-AVENTIS US LLC. ORDERING PERIOD IS JULY 1, 2025 TO JUNE 30, 2026 WITH FOUR ONE-YEAR OPTIONS"
Context & Analysis
On Nov 20, 2025, Department of Veterans Affairs to SANOFI-AVENTIS U.S. LLC for new award for human insulin with sanofi-aventis us llc. ordering period is july 1, 2025 to june 30, 2026 with four one-year options". The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 2 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.